Trials / Suspended
SuspendedNCT01684657
A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering
- Status
- Suspended
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- University of California, Irvine · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this research study is to find out the potential benefits and safety of asenapine (Saphris®) in adults who suffer from the developmental form of stuttering. It is hypothesized that individuals who are randomly assigned to asenapine will have an improvement in speech as compared to a placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Asenapine | This is an atypical antipsychotic that blocks dopamine and increase the serotonin level. |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2014-05-01
- Completion
- 2014-05-01
- First posted
- 2012-09-13
- Last updated
- 2014-05-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01684657. Inclusion in this directory is not an endorsement.